Jiangsu Langyan Life Technology Holdings Co., Ltd.

Primary objective: To evaluate the effectiveness of dexketoprofen tromethamine injection in the treatment of subjects with moderate to severe postoperative pain. Secondary objective: To evaluate the safety of dexketoprofen tromethamine injection in the treatment of subjects with moderate to severe postoperative pain.

Primary objective: To evaluate the pharmacokinetic (PK) characteristics of single and multiple intravenous infusions of dexketoprofen tromethamine injection in healthy adult subjects. Secondary objective: To preliminarily evaluate the tolerability and safety of single and multiple intravenous infusions of dexketoprofen tromethamine injection in healthy adult subjects.

The main purpose of the study is to investigate the relative bioavailability of the test preparation Iguratimod tablets (specification: 25 mg, produced by Jiangsu Yongan Pharmaceutical Co., Ltd.) and the reference preparation Iguratimod tablets (trade name: Edesin®, specification: 25 mg, produced by Hainan Xiansheng Pharmaceutical Co., Ltd. with a license) in healthy Chinese subjects after a single oral dose (fasting/postprandial), analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the test preparation Iguratimod tablets. The secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in Chinese healthy adult subjects after a single oral dose (fasting/postprandial).